Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial.
- DOI
- 10.1016/s1470-2045(25)00654-0
- Published
- 2026 Feb
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-25-00654-0,
title = {Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial.},
author = {Monga V and Okuno S and Van Tine B and Pollack SM and Weiss M and Hirbe A and Viveiros P and Schulte B and Attia S and Siontis B and Milhem MM and Charlson JA and Robinson S and Okunowo O and Frankel P and Woo D and Yoon J and Agulnik M},
year = {2026},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(25)00654-0},
url = {https://doi.org/10.1016/s1470-2045(25)00654-0}
}RIS
TY - JOUR TI - Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial. AU - Monga V AU - Okuno S AU - Van Tine B AU - Pollack SM AU - Weiss M AU - Hirbe A AU - Viveiros P AU - Schulte B AU - Attia S AU - Siontis B AU - Milhem MM AU - Charlson JA AU - Robinson S AU - Okunowo O AU - Frankel P AU - Woo D AU - Yoon J AU - Agulnik M PY - 2026 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(25)00654-0 UR - https://doi.org/10.1016/s1470-2045(25)00654-0 ER -
APA
V, M., S, O., B, V. T., SM, P., M, W., A, H., P, V., B, S., S, A., B, S., MM, M., JA, C., S, R., O, O., P, F., D, W., J, Y., & M, A. (2026). Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00654-0
Source records
- pubmed · retrieved 2026-09-26T06:30:22.309Z